Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases
Alimentary Pharmacology & Therapeutics, DOI: 10.1111/apt.13936
R. W. Winter, E. Collins, B. Cao, M. Carrellas, A. M. Crowell, J. R. Korzenik
"Higher" is > 33 ng of vitamin D
Note: Perhaps those with higher vitamin D did not even need the anti-TNF
- Inflammatory bowel diseases treated with vitamin D – Review May 2014 mentions TNF
- Vitamin D and Inflammatory Bowel Disease – review April 2015 mentions TNF
- Gut doctors becoming aware of importance of vitamin D – May 2012 mentions TNF
Studies which are in both categories of Intervention AND Gut
- Diverticular disease:12X reduction if low Vitamin D and given 100,000 IU monthly – RCT Aug 2020
- Irritable Bowel Syndrome treated by weekly 50,000 IU Vitamin D – RCT Feb 2019
- Ulcerative Colitis inflammation treated by weekly vitamin D (40,000 IU) – July 2018
- Gut bacteria of Crohn's disease patients improved by Vitamin D – March 2018
- Vitamin D changed microbiota in gut and airway, might reduce cystic fibrosis – RCT Nov 2017
- Crohn's Disease relapse rate of 3 in 8 with 1,000 IU vs 0 in 12 with 10,000 IU of Vitamin D – RCT Feb 2017
- Ulcerative colitis treated by injection of 300,000 IU of vitamin D – RCT July 2016
- IBS quality of life improved by vitamin D (50,000 IU every two weeks) – RCT May 2016
- IBS – 82 percent had low vitamin D, 3,000 IU spray helped a lot – RCT Dec 2015
- Crohn's disease treated by 2000 IU Vitamin D - RCT June 2015
- Crohn’s disease helped when vitamin D level raised above 30 ng – RCT Feb 2015
- Irritable Bowel Syndrome - can it be treated by 3000 IU of vitamin D - RCT Feb 2014
- Crohn's Disease patients normalizing their Vitamin D levels decreased risk of surgery by 44 percent – Aug 2013
- Crohn’s helped by 5000 IU vitamin D – April 2013
Studies which are in both categories of Intervention AND Rheumatoid Arthritis
- Rheumatoid Arthritis pain reduced by monthly 100,000 IU of Vitamin D – Oct 2018
- Rheumatoid arthritis reduced by 440,000 IU of Vitamin D over 4 months – Oct 2015
- High dose vitamin reduced pain of fibromyalgia, osteoarthritis, and rheumatoid arthritis - July 2015
- Just 500 IU of vitamin D helped reduce rheumatoid arthritis pain - RCT Oct 2011
Studies which are in both categories of Intervention AND Psorasis
See also web
- TNF Inhibitor Wikipedia
“A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma.” - Nutraingredients discussion of this study
Download the PDF from Vitamin D Life
Background
Vitamin D has been linked to disease activity among patients with inflammatory bowel diseases (IBD). Prior investigation has also suggested that vitamin D levels may affect duration of therapy with anti-tumour necrosis factor-α (anti-TNF-α) medications among patients with IBD.
Aim
To evaluate the relationship between vitamin D levels and odds of reaching remission while on an anti-TNF-α medication.
Methods
A total of 521 IBD patients enrolled in the Brigham and Women's IBD Centre database were eligible for inclusion. Patients treated with anti-TNF-α therapy who had vitamin D levels drawn within 6 months prior or 2 weeks after initiation of anti-TNF-α medication and who had reported remission status at 3 months were included. A logistic regression model adjusting for age, gender, IBD diagnosis, anti-TNF-α medication (infliximab vs. adalimumab) and first or subsequent anti-TNF-α medication was used to identify the effect of vitamin D level on initial response to anti-TNF-α therapy.
Results
A total of 173 patients were included in the final analysis. On logistic regression, patients with normal vitamin D levels n = 122 at the time of anti-TNF-α medication initiation had a 2.64 increased odds of remission at 3 months compared to patients with low vitamin D levels n = 51 when controlling for age, gender, diagnosis, type of anti-TNF-α medication and first or subsequent anti-TNF-α medication (OR = 2.64, 95% CI = 1.31–5.32, P = 0.0067).
Conclusions
These findings suggest that vitamin D levels may influence initial response to anti-TNF-α medication and that low vitamin D levels may pre-dispose patients to decreased odds of remission.